The carboxyl-terminal domain of receptor-associated protein facilitates proper folding and trafficking of the very low density lipoprotein receptor by interaction with the three amino-terminal ligand-binding repeats of the receptor

被引:25
作者
Savonen, R
Obermoeller, LM
Trausch-Azar, JS
Schwartz, AL
Bu, GJ
机构
[1] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA
关键词
D O I
10.1074/jbc.274.36.25877
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The 39-kDa receptor-associated protein (RAP) is a specialized antagonist that inhibits all known ligand interactions with receptors that belong to the low density lipoprotein (LDL) receptor gene family. Recent studies have demonstrated a role for RAP as a molecular chaperone for the LDL receptor-related protein during receptor folding and trafficking within the early secretory pathway. In the present study, we investigated a potential role for RAP as a chaperone for the very low density lipoprotein (VLDL) receptor, another member of the LDL receptor gene family, Using intracellular crosslinking techniques, we found that RAP is associated with newly synthesized VLDL receptor. In the absence of RAP co-expression, newly synthesized VLDL receptor exhibited slower trafficking along the early secretory pathway, most likely due to misfolding of the receptor. The role of RAP in the folding of the VLDL receptor was further studied using an anchor-free, soluble VLDL receptor. Metabolic pulse-chase labeling experiments showed that while only 3% of the soluble VLDL receptor was folded and secreted in the absence of RAP co-expression, over 50% of the soluble receptor was secreted in the presence of RAP co-expression. The functions of RAP in VLDL receptor folding and trafficking were mediated by its carboxyl-terminal repeat but not by the amino-terminal and central repeats. Using truncated VLDL receptor constructs, we identified the RAP-binding site within the first three ligand-binding repeats of the VLDL receptor. Thus, our present study demonstrates that RAP serves as a folding and trafficking chaperone for the VLDL receptor via interactions of its carboxyl-terminal repeat with the three amino-terminal ligand-binding repeats of the VLDL receptor.
引用
收藏
页码:25877 / 25882
页数:6
相关论文
共 47 条
[21]  
HERZ J, 1991, J BIOL CHEM, V266, P21232
[22]  
JOKINEN EV, 1994, J BIOL CHEM, V269, P26411
[23]   Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor [J].
Kobayashi, K ;
Oka, K ;
Forte, T ;
Ishida, B ;
Teng, BB ;
IshimuraOka, K ;
Nakamuta, M ;
Chan, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (12) :6852-6860
[24]   Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene [J].
Kozarsky, KF ;
Jooss, K ;
Donahee, M ;
Strauss, JF ;
Wilson, JM .
NATURE GENETICS, 1996, 13 (01) :54-62
[25]   STRUCTURES AND FUNCTIONS OF MULTILIGAND LIPOPROTEIN RECEPTORS - MACROPHAGE SCAVENGER RECEPTORS AND LDL RECEPTOR-RELATED PROTEIN (LRP) [J].
KRIEGER, M ;
HERZ, J .
ANNUAL REVIEW OF BIOCHEMISTRY, 1994, 63 :601-637
[26]   CLEAVAGE OF STRUCTURAL PROTEINS DURING ASSEMBLY OF HEAD OF BACTERIOPHAGE-T4 [J].
LAEMMLI, UK .
NATURE, 1970, 227 (5259) :680-+
[27]   THE 39-KDA RECEPTOR-ASSOCIATED PROTEIN MODULATES LIPOPROTEIN CATABOLISM BY BINDING TO LDL RECEPTORS [J].
MEDH, JD ;
FRY, GL ;
BOWEN, SL ;
PLADET, MW ;
STRICKLAND, DK ;
CHAPPELL, DA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (02) :536-540
[28]   BINDING AND ENDOCYTOSIS OF PROTEINS MEDIATED BY EPITHELIAL GP330 [J].
MOESTRUP, SK ;
CHRISTENSEN, EI ;
NIELSEN, S ;
JORGENSEN, KE ;
BJORN, SE ;
ROIGAARD, H ;
GLIEMANN, J .
BIOLOGY OF ALPHA2-MACROGLOBULIN, ITS RECEPTOR, AND RELATED PROTEINS, 1994, 737 :124-137
[29]  
MOKUNO H, 1994, J BIOL CHEM, V269, P13238
[30]   2 RECEPTOR SYSTEMS ARE INVOLVED IN THE PLASMA-CLEARANCE OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA) IN-VIVO [J].
NARITA, M ;
BU, GJ ;
HERZ, J ;
SCHWARTZ, AL .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (02) :1164-1168